Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q2 2023 · 10-Q
Revenue—
Net Income-$1.77M-$1.77MN/M vs Q2 2022 EPS Diluted-$5.21-$5.21N/M vs Q2 2022 Operating Income-$3,039,868N/M Operating Cash Flowderived-$3,632,673N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end